Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.

Saved in:
Bibliographic Details
Title: Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.
Authors: Subbarayan K; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Massa C; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Leisz S; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Steven A; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Bethmann D; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany., Biehl K; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany., Wickenhauser C; Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany., Seliger B; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.; Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Source: Oncoimmunology [Oncoimmunology] 2022 Apr 28; Vol. 11 (1), pp. 2069214. Date of Electronic Publication: 2022 Apr 28 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2162-402X
DOI:10.1080/2162402X.2022.2069214